Skip to main content
Top
Published in: Rheumatology International 3/2015

01-03-2015 | Original Article - Genes and Disease

The CC chemokine ligand 2 (CCL2) polymorphism −2518A/G is associated with gout in the Chinese Han male population

Authors: Ruixia Sun, Keke Zhang, Xiaokun Zhang, Lingling Cui, Can Wang, Qingsheng Mi, Shiguo Liu, Changgui Li

Published in: Rheumatology International | Issue 3/2015

Login to get access

Abstract

Gout is usually characterized by uric acid-induced recurrent attacks of acute inflammatory arthritis. CC chemokine ligand 2 (CCL2), a chemokine involved in the recruitment and migration of monocytes/macrophages, has previously been shown to be increased in the plasma of gout patients. In this study, we examined whether the CCL2 −2518A/G (rs1024611) single nucleotide polymorphism (SNP) affects susceptibility to gout in a Chinese Han male population. Genomic DNA from gout patients (n = 1,109) and ethnically matched gout-free controls (n = 1,034) was genotyped for the CCL2 −2518A/G SNP using polymerase chain reaction–restriction fragment length polymorphism. The Chi-square test was performed to investigate the association of genotypic and allelic frequencies between cases and controls, and the −2518G allele was shown to be associated with a significantly increased risk of gout development [P = 0.007, odds ratio 1.182, 95 % confidence interval 1.047–1.335]. The GG genotypic distribution was also significantly different between cases and controls (adjusted P = 0.021). However, genotypic distributions and allelic frequencies did not indicate significant associations (P = 0.150 and P = 0.050, respectively) between tophi and non-tophi patients. Our findings support a key role for the CCL2 SNP −2518A/G in association with gout susceptibility in the Chinese Han male population. However, additional studies in other populations should be carried out to confirm this finding.
Literature
2.
go back to reference Matsukawa A, Miyazaki S, Maeda T, Tanase S, Feng L et al (1998) Production and regulation of monocyte chemoattractant protein-1 in lipopolysaccharide-or monosodium urate crystal-induced arthritis in rabbits: roles of tumor necrosis factor alpha, interleukin-1, and interleukin-8. Lab Invest 78:973–985PubMed Matsukawa A, Miyazaki S, Maeda T, Tanase S, Feng L et al (1998) Production and regulation of monocyte chemoattractant protein-1 in lipopolysaccharide-or monosodium urate crystal-induced arthritis in rabbits: roles of tumor necrosis factor alpha, interleukin-1, and interleukin-8. Lab Invest 78:973–985PubMed
3.
go back to reference Zheng W, Li R, Pan H, He D, Xu R et al (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β through the NF-κB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60:1957–1965CrossRefPubMed Zheng W, Li R, Pan H, He D, Xu R et al (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β through the NF-κB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60:1957–1965CrossRefPubMed
4.
go back to reference Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K et al (1993) Monocyte chemoattractant protein-1 (CCL2) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 69:83–91CrossRefPubMed Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K et al (1993) Monocyte chemoattractant protein-1 (CCL2) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 69:83–91CrossRefPubMed
5.
go back to reference Grainger R, McLaughlin RJ, Harrison AA, Harper JL (2013) Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatology 52:1018–1021CrossRefPubMed Grainger R, McLaughlin RJ, Harrison AA, Harper JL (2013) Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatology 52:1018–1021CrossRefPubMed
6.
go back to reference Fenoglio et al. (2004) CCL2 in Alzheimer’s disease patients: a −2518G polymorphism and serum levels by neurobiol aging 25(9):1169–1173 Fenoglio et al. (2004) CCL2 in Alzheimer’s disease patients: a −2518G polymorphism and serum levels by neurobiol aging 25(9):1169–1173
7.
go back to reference Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M et al (2005) The −2518 promotor polymorphism in the CCL2 gene is associated with systemic sclerosis. J Invest Dermatol 124:92–98CrossRefPubMed Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M et al (2005) The −2518 promotor polymorphism in the CCL2 gene is associated with systemic sclerosis. J Invest Dermatol 124:92–98CrossRefPubMed
8.
go back to reference Gao Q, Du Q, Zhang H, Guo C, Lu S et al (2014) Monocyte chemotactic protein-1 −2518 gene polymorphism and susceptibility to spinal tuberculosis. Arch Med Res 45:183–187CrossRefPubMed Gao Q, Du Q, Zhang H, Guo C, Lu S et al (2014) Monocyte chemotactic protein-1 −2518 gene polymorphism and susceptibility to spinal tuberculosis. Arch Med Res 45:183–187CrossRefPubMed
9.
go back to reference Song GG, Lee YH (2013) The CTLA-4 and CCL2 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis. Immunol Invest 42:481–492CrossRefPubMed Song GG, Lee YH (2013) The CTLA-4 and CCL2 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis. Immunol Invest 42:481–492CrossRefPubMed
10.
go back to reference Lin HL, Ueng KC, Hsieh YS, Chiang WL, Yang SF et al (2012) Impact of CCL2 and CCR-2 gene polymorphisms on coronary artery disease susceptibility. Mol Biol Rep 39:9023–9030CrossRefPubMed Lin HL, Ueng KC, Hsieh YS, Chiang WL, Yang SF et al (2012) Impact of CCL2 and CCR-2 gene polymorphisms on coronary artery disease susceptibility. Mol Biol Rep 39:9023–9030CrossRefPubMed
11.
go back to reference Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS et al (2007) Monocyte chemoattractant protein-1: plasma concentrations and A (−2518) G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746PubMed Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS et al (2007) Monocyte chemoattractant protein-1: plasma concentrations and A (−2518) G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746PubMed
12.
go back to reference Miao Z, Li C, Chen Y, Zhao S, Wang Y et al (2008) Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 35:1859–1864PubMed Miao Z, Li C, Chen Y, Zhao S, Wang Y et al (2008) Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 35:1859–1864PubMed
13.
go back to reference Luk AJ, Simkin PA (2005) Epidemiology of hyperuricemia and gout. Am J Manag Care 11:S435–S442PubMed Luk AJ, Simkin PA (2005) Epidemiology of hyperuricemia and gout. Am J Manag Care 11:S435–S442PubMed
14.
go back to reference Sundy JS, Hershfield MS (2007) Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 9:258–264CrossRefPubMed Sundy JS, Hershfield MS (2007) Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 9:258–264CrossRefPubMed
15.
go back to reference Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900CrossRefPubMed Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900CrossRefPubMed
16.
go back to reference Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr et al (2005) Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMedCentralPubMed Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr et al (2005) Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMedCentralPubMed
17.
go back to reference Pierer M, Rethage J, Seibl R, Lauener R, Brentano F et al (2004) Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 172:1256–1265CrossRefPubMed Pierer M, Rethage J, Seibl R, Lauener R, Brentano F et al (2004) Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 172:1256–1265CrossRefPubMed
18.
go back to reference Yao TC, Kuo ML, See LC, Ou LS, Lee WI et al (2006) RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 54:258–2593CrossRef Yao TC, Kuo ML, See LC, Ou LS, Lee WI et al (2006) RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 54:258–2593CrossRef
19.
go back to reference Ogura N, Satoh K, Akutsu M, Tobe M, Kuyama K et al (2010) CCL2 production in temporomandibular joint inflammation. J Dent Res 89:1117–1122CrossRefPubMed Ogura N, Satoh K, Akutsu M, Tobe M, Kuyama K et al (2010) CCL2 production in temporomandibular joint inflammation. J Dent Res 89:1117–1122CrossRefPubMed
20.
go back to reference Ahmed S, Pakozdi A, Koch AE (2006) Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 54:2393–2401CrossRefPubMed Ahmed S, Pakozdi A, Koch AE (2006) Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 54:2393–2401CrossRefPubMed
21.
go back to reference Liu S, Yin C, Chu N, Han L, Li C (2013) IL-8-251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population. Scand J Rheumatol 42:150–158CrossRefPubMed Liu S, Yin C, Chu N, Han L, Li C (2013) IL-8-251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population. Scand J Rheumatol 42:150–158CrossRefPubMed
22.
go back to reference Liu S, Wang H, Li C (2013) Relationship between -238A/G and -308A/G polymorphisms in the promoter region of TNF-α and susceptibility to gout in the Chinese Han male population. Cent Eur J Immunol 38:449–453CrossRef Liu S, Wang H, Li C (2013) Relationship between -238A/G and -308A/G polymorphisms in the promoter region of TNF-α and susceptibility to gout in the Chinese Han male population. Cent Eur J Immunol 38:449–453CrossRef
23.
go back to reference Chang SJ, Chen CJ, Tsai FC, Lai HM, Tsai PC et al (2008) Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor beta1 gene. Rheumatology 47:617–621CrossRefPubMed Chang SJ, Chen CJ, Tsai FC, Lai HM, Tsai PC et al (2008) Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor beta1 gene. Rheumatology 47:617–621CrossRefPubMed
24.
go back to reference Chang SJ, Tsai PC, Chen CJ, Lai HM, Ko YC (2007) The polymorphism −863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology 46:1662–1666CrossRefPubMed Chang SJ, Tsai PC, Chen CJ, Lai HM, Ko YC (2007) The polymorphism −863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology 46:1662–1666CrossRefPubMed
25.
go back to reference Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the CCL2 gene regulatory region that influences CCL2 expression. Biochem Biophys Res Commun 259:344–348CrossRefPubMed Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the CCL2 gene regulatory region that influences CCL2 expression. Biochem Biophys Res Commun 259:344–348CrossRefPubMed
26.
go back to reference Pham MH, Bonello GB, Castiblanco J et al (2012) The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS ONE 7(11):e49498CrossRefPubMedCentralPubMed Pham MH, Bonello GB, Castiblanco J et al (2012) The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS ONE 7(11):e49498CrossRefPubMedCentralPubMed
Metadata
Title
The CC chemokine ligand 2 (CCL2) polymorphism −2518A/G is associated with gout in the Chinese Han male population
Authors
Ruixia Sun
Keke Zhang
Xiaokun Zhang
Lingling Cui
Can Wang
Qingsheng Mi
Shiguo Liu
Changgui Li
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3102-3

Other articles of this Issue 3/2015

Rheumatology International 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.